戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tion of the bone protein matrix (rickets and osteomalacia).
2  in vivo and in the etiology of drug-induced osteomalacia.
3 lates extracellularly, leading to rickets or osteomalacia.
4 t and C-terminal Fgf23 with hypophosphatemic osteomalacia.
5 an disease X-linked hypophosphatemic rickets/osteomalacia.
6  and low bone mineral density as a result of osteomalacia.
7 th a high risk of fragility fractures due to osteomalacia.
8 atemia, renal phosphate wasting, and rickets/osteomalacia.
9 taflox/y, and hyp-mice manifested comparable osteomalacia.
10 rum fibroblast growth factor-23 (Fgf23), and osteomalacia.
11 tion of 1,25-dihydroxyvitamin D, and rickets/osteomalacia.
12 ng a new molecular mechanism of drug-induced osteomalacia.
13 iating vitamin D catabolism and drug-induced osteomalacia.
14 nal effects of the hormone and contribute to osteomalacia.
15 malities, secondary hyperparathyroidism, and osteomalacia.
16 g adults and causes the painful bone disease osteomalacia.
17 7.08 microM [0.9-3.7 mg/dL]) and evidence of osteomalacia.
18 in the serum of a patient with tumor-induced osteomalacia.
19 to correct the hypophosphatemia, rickets, or osteomalacia.
20 with osteomalacia and 12 patients with focal osteomalacia.
21  of secondary hyperparathyroidism and severe osteomalacia.
22 phosphatase (TNSALP), results in rickets and osteomalacia.
23 ocalcemia, hyperparathyroidism, rickets, and osteomalacia.
24 he most common heritable form of rickets and osteomalacia.
25 itamin D levels, hypercalciuria, and rickets/osteomalacia.
26  secondary hyperparathyroidism, rickets, and osteomalacia, accompanied by 90% reduction in renal CaBP
27 87.5% of patients, including 9 patients with osteomalacia and 12 patients with focal osteomalacia.
28 milliliter in those with suspected oncogenic osteomalacia and 353+/-510 RU per milliliter (range, 31
29                  However, the latter, mostly osteomalacia and increased bone resorption, cannot be re
30 amin D deficiency (hypovitaminosis D) causes osteomalacia and poor long bone mineralization.
31 <10 ng/mL, which are concentrations at which osteomalacia and rickets occur).
32 ate kinase (PGK) promoter completely avoided osteomalacia and secondary hyperparathyroidism, and simu
33 er osteodystrophy characterized initially by osteomalacia and, more recently, by adynamic or aplastic
34 ophosphatemia, hyperparathyroidism, rickets, osteomalacia, and alopecia--the last a consequence of de
35 o down-regulate NPT2a, causing P(i) wasting, osteomalacia, and decreased BMD.
36 rfism, decreased bone mineral density (BMD), osteomalacia, and decreased serum phosphate (P(i)).
37  hypophosphatemia, characterized by rickets, osteomalacia, and hypomineralized dentin formation, a ph
38  low bone turnover, and generalized or focal osteomalacia are frequent histologic features in transpl
39                                  Rickets and osteomalacia are seen by day 35; however, as early as da
40 ) in mice, or its mutation in humans, causes osteomalacia believed to reflect renal phosphate wasting
41  5.4 +/- 0.1 mg/dl), and severity of rickets/osteomalacia (bone mineral density: -36, -36, and -30%).
42 mal serum calcidiol may avoid the problem of osteomalacia, but it does not correct malabsorption of c
43 ice, its putative role as an auto-/paracrine osteomalacia-causing factor has not been explored.
44 nant hypophosphatemic rickets, and oncogenic osteomalacia demonstrate that elevated levels of novel c
45                       Tumors associated with osteomalacia elaborate the novel factor(s), phosphatonin
46                 Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970
47 lexural strength, and histologic evidence of osteomalacia; however, cultures of Hyp-derived bone marr
48 otypic changes, including dwarfism, rickets, osteomalacia, hypophosphatemia, increased serum parathyr
49 CasR deficiency, indicating that rickets and osteomalacia in CasR-deficient mice are not due to an in
50 s disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23
51 he concentrations associated with rickets or osteomalacia influence calcium absorption.
52            The pathogenesis of tumor-induced osteomalacia involves tumor expression of fibroblast gro
53                                Tumor-induced osteomalacia is a rare acquired metabolic disorder chara
54           Vitamin D deficiency, which causes osteomalacia, may also be important in the pathogenesis
55 5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0+/-13.3 years) and 21 patien
56 alization defects in the skeleton and teeth (osteomalacia/odontomalacia).
57                                    Thus, the osteomalacia of Akp2-/- mice and the hypomineralized phe
58                   Oncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate
59 ether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometr
60 be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting th
61         Additional skeletal features include osteomalacia, thinned/porous cortical bone, reduced proc
62                                              Osteomalacia was diagnosed in one patient.
63 al agent rifampin, resulting in drug-induced osteomalacia, which is attributed to vitamin D deficienc
64 pophosphatemic rickets, manifest rickets and osteomalacia with isolated renal phosphate-wasting assoc
65  content, expanded growth plates, and severe osteomalacia, with highly increased bone Fgf23 mRNA (>15

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。